Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma.
about
Formulation and in vitro, in vivo evaluation of effervescent floating sustained-release imatinib mesylate tabletMulticentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastomaPhase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).Simple methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib.Imatinib assay by high-performance liquid chromatography in tandem mass spectrometry with solid-phase extraction in human plasma.Will imatinib compromise reproductive capacity?Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancerSimultaneous quantification of imatinib and its main metabolite N-demethyl-imatinib in human plasma by liquid chromatography-tandem mass spectrometry and its application to therapeutic drug monitoring in patients with gastrointestinal stromal tumor.Imatinib-induced immune hepatitis: case report and literature review.Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy.Quantification of imatinib in human serum: validation of a high-performance liquid chromatography-mass spectrometry method for therapeutic drug monitoring and pharmacokinetic assays.Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant gliomaA phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancerEffect of antacid on imatinib absorptionA high-performance liquid chromatography-mass spectrometry assay for quantitation of the tyrosine kinase inhibitor nilotinib in human plasma and serum.Effect of a proton pump inhibitor on the pharmacokinetics of imatinib.Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteersPhase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042.Antineoplastic drugs and their analysis: a state of the art review.Conformational landscape and low lying excited states of imatinib.Comment on: Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance.Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance.Therapeutic drug monitoring and tyrosine kinase inhibitors.Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia.Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia.Severe hepatitis and complete molecular response caused by imatinib mesylate: possible association of its serum concentration with clinical outcomes.Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.Biliary excretion of imatinib mesylate and its metabolite CGP 74588 in humans.Chronic myeloid leukemia and HIV-infection.Determination of imatinib and its active metabolite N-desmethyl imatinib in human plasma by liquid chromatography/tandem mass spectrometry.Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia.Renal dysfunction in a renal transplant patient treated concurrently with cyclosporine and imatinib.Capillary electrophoresis method for plasmatic determination of imatinib mesylate in chronic myeloid leukemia patients.
P2860
Q28547738-B3F2B0EA-D666-4B0A-9000-7C667CB81B57Q33387009-0F5F4CAF-B13C-443B-AC72-F27938F06B23Q33574578-DDA872F3-05B8-4BA3-9159-5505CD0C9BCAQ34377463-C4BBEE69-2C3D-4047-AF46-FF93336CB023Q34433289-57AACA94-02D7-4BC4-B90D-FFE3B30A13E6Q35584349-844584FC-0D21-4598-96A1-2685CD135265Q36166836-739A7E42-9BCB-4995-9DC5-A206B38FE240Q36407123-623F0041-B9D2-496C-AD3A-130504ACF8ABQ36761730-69BFD73E-E78E-402E-8266-916404585039Q36926767-65B43011-35E0-4185-A8C6-D698D092318FQ36988077-0EC9FF25-B27F-4815-AB43-2D275FED3C78Q37085189-75937142-6B32-43DE-B165-C583D736173AQ37214249-741E7270-94EF-4C01-B0D5-FA79EE1D3E65Q37214382-E9F908BC-270F-4767-83AD-5CD5887A0732Q37273401-5562A23C-3ADC-44CB-B5ED-B3B5E9750A98Q37381751-8912611E-1FC2-411C-B0FE-2EA8D48700E8Q37397785-5F6A4B0B-8328-47D9-B6AB-F5B636D83677Q37432684-273FF531-BE17-4EF2-AD48-6F0D750881A9Q37549881-BA5D3FCD-8270-43B7-A8DF-6B0A0F89F4DEQ39339684-49351E68-C9B9-4755-84D7-A2B0B763C589Q41237029-35A0F987-60A8-4C8E-A3AD-93869ED4299FQ41501511-0AF6DC67-33E9-473B-A9F9-907E034068DDQ41501849-FDBE77DE-EEE9-4151-AA56-4B23780BCAE7Q41846251-1BFFCF3F-4D52-4FB2-8143-9EB4C2AB08EBQ42933358-7EC6F7AC-4441-4D4D-8473-317727DD377AQ43288117-090FBF7C-D696-41D0-AD30-A27CD7F42AA8Q43628935-8A082D1F-E265-41ED-A5A6-1198B036DDF7Q43841175-F015453C-323B-401F-806F-3C46AD17F349Q45087236-B5D67286-ED87-4A9D-8FFE-F591EB08F164Q46615390-BF837CF5-6D43-4BD2-B906-4BC947D5515CQ51336894-1326992A-009C-4700-A717-08E7018D117AQ54222903-7DDED6C2-C885-437A-85AD-29733663675DQ54547524-AFCC03FB-2E43-4184-8330-73F26B78FC76Q54578490-5C56E207-36AF-4767-BDB8-FF931F3430FF
P2860
Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Liquid chromatographic-mass sp ...... abolite (CGP 74588) in plasma.
@en
type
label
Liquid chromatographic-mass sp ...... abolite (CGP 74588) in plasma.
@en
prefLabel
Liquid chromatographic-mass sp ...... abolite (CGP 74588) in plasma.
@en
P2093
P1476
Liquid chromatographic-mass sp ...... abolite (CGP 74588) in plasma.
@en
P2093
Merrill J Egorin
Michael J Hayes
Ramesh K Ramanathan
Robert A Parise
P356
10.1016/S1570-0232(03)00206-X
P577
2003-07-01T00:00:00Z